Prenetics (PRE) said Wednesday it has completed the sale of ACT Genomics to Delta Electronics in a deal valued at up to $71.8 million.
The divestment strengthens Prenetics' financial position, raising pro-forma cash reserves to approximately $86 million, the company said.
Prenetics' focus will now shift to growing its high-margin consumer health brands IM8, CircleDNA, and Europa, following the strategic transformation, it said.
Prenetics raised its full-year 2025 revenue guidance to $80-100 million, driven by strong growth in its consumer health segment, the company said.
Shares of the company were up over 10% in recent Wednesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.